Research programme: anti-hFcRn mAbs - HanAll BioPharma

Drug Profile

Research programme: anti-hFcRn mAbs - HanAll BioPharma

Alternative Names: HanAll's anti-hFcRn mAbs; HL-161

Latest Information Update: 21 Sep 2016

Price : $50

At a glance

  • Originator HanAll Biopharma
  • Class Monoclonal antibodies
  • Mechanism of Action Fc receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Lupus nephritis; Myasthenia gravis; Neuromyelitis optica; Pemphigus

Most Recent Events

  • 14 Aug 2015 HL 161 is available for licensing
  • 25 Feb 2015 HanAll Biopharma receives KWR 2.4 billion from Korean Drug Development Fund
  • 25 Feb 2015 HanAll Biopharma plans to file for the IND application in 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top